.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,160,870

« Back to Dashboard
Patent 7,160,870 protects PROMACTA and is included in two NDAs. There have been two Paragraph IV challenges on Promacta.

Protection for PROMACTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-four patent family members in twenty-eight countries.

Summary for Patent: 7,160,870

Title:Thrombopoietin mimetics
Abstract:Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s): Duffy; Kevin J. (Collegeville, PA), Erickson-Miller; Connie (King Of Prussia, PA), Jenkins; Julian (Collegeville, PA), Luengo; Juan I. (Collegeville, PA), Visonneau; Sophie (Thousand Oaks, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA) Glaxo Group Limited (Greenford, GB)
Application Number:10/296,688
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Delivery; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 58th percentile
Forward Citations: 18th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
FOR SUSPENSION;ORAL207027-001Aug 24, 2015RXYes7,160,870► subscribeYY TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXNo7,160,870*PED► subscribeY
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-001Nov 20, 2008RXNo7,160,870*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,160,870

PCT Information
PCT FiledMay 24, 2001PCT Application Number:PCT/US01/16863
PCT Publication Date:November 29, 2001PCT Publication Number: WO01/89457

Non-Orange Book Patents for Patent: 7,160,870

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,704Thrombopoietin mimetics► subscribe
7,452,874Thrombopoietin mimetics► subscribe
7,335,649Thrombopoietin mimetics► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,160,870

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina030696► subscribe
Argentina066036► subscribe
Austria374772► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc